Clinical trials: Methylphenidate, completed
ADHD, Attention Deficit Hyperactivity Disorder
Study of Atomoxetine and OROS Methylphenidate to Treat Children and Adolescents Ages 6-17 With ADHD
The purpose of this study is to evaluate the safety, effectiveness, and tolerability of atomoxetine and OROS methylphenidate, taken together, in the treatment of ADHD in children and adolescents ages 6-17.
- Trial name
- NCT00585910
- Testing
- Atomoxetine and OROS Methylphenidate
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- Massachusetts General Hospital
Attention Deficit Disorder With Hyperactivity
Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy
This study will assess the safety and tolerability of MTS while attempting to establish the appropriate starting dose for subjects previously on an existing long-acting methylphenidate product.
- Trial name
- NCT00151983
- Testing
- Methylphenidate Transdermal System
- Where
- 18 sites in United States
- Volunteers
- 175 people
- Sponsor
- Noven Therapeutics
Attention Deficit-Hyperactivity Disorder
Real World Evidence of the Efficacy and Safety of FOQUEST
This study is a four-month, phase IV, open-label study of ADHD symptomatology and functional outcomes in pediatric (6 to 17 years old) and adult (≥18 years or older) patients with ADHD treated with FOQUEST or VYVANSE.
- Trial name
- reFOQus (NCT04152629)
- Testing
- Methylphenidate Hydrochloride, Lisdexamfetamine Dimesylate
- Where
- 12 sites in Canada
- Volunteers
- 257 people
- Sponsor
- Purdue Pharma, Canada
Attention Deficit Disorder With Hyperactivity
Treatment of Severe Childhood Aggression (The TOSCA Study)
This study will determine the safety and effectiveness of two medications for treating aggression in children with attention deficit hyperactivity disorder (ADHD).
- Trial name
- NCT00796302
- Testing
- Methylphenidate HCl, Risperidone, Parent Management Training (PMT)
- Where
- 4 sites in United States
- Volunteers
- 168 people
- Sponsor
- Michael Aman
Attention Deficit Hyperactivity Disorder
Efficacy of GXR as Adjunctive Therapy With Psycho-stimulant on Executive Function in Children With ADHD
This study looks to examine whether or not INTUNIV extended release can help children aged 6-12 years diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD) in improving Executive Function when added to their usual care…
- Trial name
- NCT01985581
- Testing
- Guanfacine extended release, Stimulant therapy
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- JPM van Stralen Medicine Professional
Attention-Deficit/Hyperactivity Disorder (ADHD)
Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.
This study will evaluate the efficacy and safety of Dex-Methylphenidate Extended Release 30 mg compared to 20 mg in pediatric patients ages 6-12 with Attention-Deficit Hyperactivity Disorder (ADHD) in a 12-hour laboratory…
- Trial name
- NCT00776009
- Testing
- Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR)
- Where
- 8 sites in United States
- Volunteers
- 165 people
- Sponsor
- Novartis Pharmaceuticals
Attention-Deficit/Hyperactivity Disorder (ADHD)
Does Active Parent Involvement in Deliberation and Choice Improve Medication Persistence for Their Child With ADHD
The purpose of the study is to determine whether active parent involvement in deliberation and choice improves subsequent medication persistence for their child with ADHD.
- Trial name
- NCT00631280
- Testing
- Choice, Recommendation
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Attention Deficit Disorder With Hyperactivity
Stimulant Versus Nonstimulant Medication for Attention Deficit Hyperactivity Disorder in Children
This study will determine the effectiveness of stimulant and nonstimulant medication in treating the symptoms of attention deficit hyperactivity disorder (ADHD) in children and adolescents.
- Trial name
- NCT00183391
- Testing
- Atomoxetine, Methylphenidate
- Where
- 2 sites in United States
- Volunteers
- 232 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Attention Deficit Hyperactivity Disorder
OT and Social Cognition in Children With ADHD: Impact of MPH
Background: The current study aimed to explore the possible effect of stimulants on oxytocin (OT), a neuropeptide found to regulate social behavior, as a mediator of the pro-social effect of methylphenidate (MPH) in children with…
- Trial name
- NCT03788902
- Testing
- Ritalin
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Shalvata Mental Health Center
Attention Deficit Hyperactivity Disorder
An Effectiveness and Safety Study of CONCERTA* vs. Immediate Release Methylphenidate (IR MPH) in Attention Deficit Hyperactivity Disorder Children
The purpose of this study is to determine the effectiveness and safety of OROS*methylphenidate/CONCERTA* vs. immediate release methylphenidate as a treatment for ADHD specifically for those children who have behavioural…
- Trial name
- NCT00304681
- Testing
- OROS*-Methylphenidate
- Volunteers
- 147 people
- Sponsor
- Janssen-Ortho Inc., Canada
ADHD
Basic and Clinical Research on Attention Deficit Hyperactivity Disorder (ADHD)
Children between 6-17 are evaluated for ADHD and and a blood sample is obtained for DNA extraction. If eligible, they participate in a 4 week, double blind, placebo controlled trial with weekly switches.
- Trial name
- NCT00663442
- Testing
- OROS methylphenidate
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- University of Illinois Chicago
Attention Deficit Disorder With Hyperactivity, Conduct Disorder
Medication Strategies for Treating Aggressive Behavior in Youth With Attention Deficit Hyperactivity Disorder
This study will assess whether adding a mood stabilizer, divalproex sodium, to stimulant treatment is more effective than stimulant treatment alone in reducing aggressive behavior among children with attention deficit…
- Conditions
- Attention Deficit Disorder With Hyperactivity, Conduct Disorder, Oppositional Defiant Disorder
- Trial name
- NCT00228046
- Testing
- Divalproex Sodium, Methylphenidate, Dextroamphetamine
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Stony Brook University
Attention Deficit Disorder With Hyperactivity
A Study of Label Compliance for Attention Deficit/Hyperactivity Disorder (ADHD) Medications in Japan
The purpose of this study is to document the extent of on-label and off-label use of Methylphenidate (MPH) (Concerta), MPH (Ritalin), Atomoxetine (ATO), and Guanfacine (GFC) in Japan.
- Trial name
- NCT04113551
- Testing
- MPH (Concerta), MPH (Ritalin), Atomoxetine (ATO)
- Where
- United States
- Volunteers
- 17,418 people
- Sponsor
- Janssen Research & Development, LLC
Disruptive Mood Dysregulation Disorder
Aripiprazole Added on for DMDD in Youths With ADHD
Objectives: 1. To investigate the effectiveness of adjuvant with aripiprazole to methylphenidate for disruptive mood dysregulation disorder (DMDD) in youths with attention-deficit/hyperactivity disorder (ADHD) 2.
- Trial name
- AAOFDIYWA (NCT03358277)
- Testing
- MPH + APZ
- Volunteers
- 58 people
- Sponsor
- Tri-Service General Hospital (TSGH)
ADHD, Probiotics
Effect of Probiotics on ADHD
Attention-Deficit/Hyperactivity Disorder (ADHD) is a common neurodevelopmental disorder. Gut microbiome dysbiosis may be associated with the pathophysiology of ADHD.
- Conditions
- ADHD, Probiotics, Gut Microbiota, Psychiatry
- Trial name
- NCT04958460
- Testing
- BF688
- Where
- Taiwan
- Volunteers
- 150 people
- Sponsor
- Wang Liang-Jen
Acute Lymphoblastic Leukemia, Brain Tumors
Learning Impairments Among Survivors of Childhood Cancer
Children surviving some types of cancer have a higher risk of developing learning problems after cancer treatment than do children who have not had cancer or its treatment.
- Trial name
- NCT00576472
- Testing
- Methylphenidate
- Where
- 3 sites in United States
- Volunteers
- 469 people, healthy volunteers welcome
- Sponsor
- St. Jude Children's Research Hospital
Attention Deficit Hyperactivity Disorder, ADHD
Efficacy and Safety of Methylphenidate HCl ER Capsules in Children and Adolescents With ADHD
This multi-center parallel study is designed to study the efficacy and safety of fixed doses of methylphenidate extended release (ER) capsules of four dose levels compared with a placebo group in pediatric patients with Attention…
- Trial name
- NCT01239030
- Testing
- Methylphenidate Hydrochloride Extended Release Capsules
- Where
- 16 sites in United States
- Volunteers
- 230 people
- Sponsor
- Rhodes Pharmaceuticals, L.P.
Attention Deficit Hyperactivity Disorder
Large-scale Brain Organization During Cognitive Control in ADHD
The purpose of this study is to test whether children with attention-deficit/hyperactivity disorder (ADHD) are impaired in the ability to flexibly adapt brain network organization in response to shifting cognitive demands during…
- Trial name
- NCT04349917
- Testing
- Methylphenidate
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- University of North Carolina, Chapel Hill
Attention Deficit Hyperactivity Disorder, ADHD
Imaging Stimulant and Non Stimulant Treatments for ADHD: A Network Based Approach
The growing number of medications used to treat attention-deficit/hyperactivity disorder (ADHD) raises important questions about whether different medications have similar or different therapeutic mechanisms of action.
- Trial name
- NCT01678209
- Testing
- fMRI scans, Atomoxetine arm, Methylphenidate arm
- Where
- United States
- Volunteers
- 127 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Attention Deficit Hyperactivity Disorder
Clinical and Pharmacogenetic Study of Attention Deficit With Hyperactivity Disorder (ADHD)
Attention deficit with hyperactivity disorder (ADHD) is a very common behavioral problem during childhood. It is estimated that up to 80% of this disorder could be related to genetic factors.
- Trial name
- NCT00483106
- Testing
- Ritalin
- Where
- Canada
- Volunteers
- 885 people
- Sponsor
- McGill University